Literature DB >> 15871070

[Probiotics as therapeutic agents in irritable bowel syndrome].

H-J Krammer1, F Schlieger, H Harder, A Franke, M V Singer.   

Abstract

Probiotics are defined as living micro-organisms which, when administered in large amounts, confer a health benefit on the host. The use of probiotics in the therapy of infectious bowel diseases as well as maintaining remission of ulcerative colitis and in pouchitis is evidence-based. Also, in several studies proof could be supplied that specific probiotics relieve the symptoms and the course of irritable bowel syndrome. Some trials showed a significant improvement of irritable bowel syndrome-related constipation via Lactobacillus casei Shirota and E. coli Nissle 1917. Lactobacillus plantarum has been proven effective in reducing pain and abdominal bloating. However, in most of the studies rather small numbers of patients were examined. Furthermore, these studies do not always closely follow scientific standards (randomised, double-blind, placebo-controlled). Therefore, confirmatory studies are necessary to examine the effect of probiotics in irritable bowel syndrome.

Entities:  

Mesh:

Year:  2005        PMID: 15871070     DOI: 10.1055/s-2004-813934

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  5 in total

Review 1.  Probiotics manipulate host cytokine response and induce antimicrobial peptides.

Authors:  I Trebichavský; I Splíchal
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

Review 2.  [Therapeutic options of chronic constipation].

Authors:  H Krammer; F Schlieger; M V Singer
Journal:  Internist (Berl)       Date:  2005-12       Impact factor: 0.743

3.  Evaluation of safety and probiotic properties of a strain of Enterococcus faecium isolated from chicken bile.

Authors:  Youfei Shi; Mengkai Zhai; Jinlian Li; Baoquan Li
Journal:  J Food Sci Technol       Date:  2019-09-11       Impact factor: 2.701

4.  In vitro assessment of Enterococcus faecalis MTC 1032 as the potential probiotic in food supplements.

Authors:  Sirikhwan Tinrat; Piyatip Khuntayaporn; Krit Thirapanmethee; Mullika Traidej Chomnawang
Journal:  J Food Sci Technol       Date:  2018-04-26       Impact factor: 2.701

5.  A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome.

Authors:  Lesley M Roberts; Deborah McCahon; Roger Holder; Sue Wilson; F D Richard Hobbs
Journal:  BMC Gastroenterol       Date:  2013-03-07       Impact factor: 3.067

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.